SCHEDULE: State Street Corp. Discloses Stake in Syndax Pharmaceuticals

State Street Corporation has updated its beneficial ownership filing for Syndax Pharmaceuticals Inc., reporting a 6.4% stake as of June 30, 2026.

Summary

• State Street Corporation has filed a Schedule 13G, indicating a change in its beneficial ownership of Syndax Pharmaceuticals Inc. common stock.
• As of June 30, 2026, State Street Corporation beneficially owns 5,658,465 shares of Syndax Pharmaceuticals Inc. common stock.
• This represents 6.4% of the class of securities.
• The filing indicates shared voting power for 5,408,786 shares and shared dispositive power for 5,658,465 shares.
• State Street Corporation holds these shares in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• State Street Corporation's increased stake may signal confidence in Syndax Pharmaceuticals' long-term prospects.
• The filing is a routine disclosure, indicating standard investment management practices by State Street.

Negatives

• The filing does not provide any new operational or financial performance data for Syndax Pharmaceuticals.
• The disclosure is a passive filing and does not indicate any active strategic involvement or new investment thesis from State Street.

Risks

• Potential for future share sales by State Street Corporation could impact Syndax Pharmaceuticals' stock price.
• Changes in State Street's investment strategy could lead to significant shifts in beneficial ownership.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding Syndax Pharmaceuticals' future performance. It is a disclosure of beneficial ownership by State Street Corporation.

Management Comments

• State Street Corporation certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional investors like State Street Corporation frequently adjust their holdings in publicly traded companies. This filing reflects a significant, but not controlling, stake in Syndax Pharmaceuticals, a biotechnology company, which is typical for asset managers operating in the healthcare sector.

Stakeholder Impact

• Shareholders of Syndax Pharmaceuticals may view State Street's stake as a sign of institutional support, potentially influencing investor sentiment.
• The market may interpret this filing as a signal of institutional interest, which could affect trading activity.

Next Steps

• State Street Corporation will continue to hold or adjust its beneficial ownership of Syndax Pharmaceuticals' common stock.
• Future filings will be made by State Street Corporation if ownership levels change significantly.

Key Dates

Keywords

State Street Corporation, Syndax Pharmaceuticals, Schedule 13G, Beneficial Ownership, Institutional Investor, Healthcare, Biotechnology